2013-03-21 17:28:55 -

ORION CORPORATION        STOCK EXCHANGE RELEASE 21 MARCH 2013 at 6.25
p.m. EET


Orion Corporation has submitted a marketing authorisation application for
combined budesonide-formoterol formulation of the Easyhaler® product family in
Europe. Orion applies for approval in European Union through decentralised
procedure. The review process will commence once all involved member states have
validated the application.




Orion Corporation





Timo Lappalainen    Reijo Salonen
President and CEO   SVP, Research and Development




Contact person:
Reijo Salonen, SVP, Research and Development, phone +358 50 966 3647



Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi


Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company   is continuously developing new drugs and
treatment methods. Pharmaceutical R&D focuses on central nervous system drugs,
oncology and critical care drugs, and Easyhaler® pulmonary drugs.

Orion's net sales in 2012 amounted to EUR 980 million and the company had about
3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.



This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: Orion Oyj via Thomson Reuters ONE
[HUG#1687256]